Country: Canada
Language: English
Source: Health Canada
MEPOLIZUMAB
GLAXOSMITHKLINE INC
R03DX09
MEPOLIZUMAB
100MG
SOLUTION
MEPOLIZUMAB 100MG
SUBCUTANEOUS
15G/50G
Prescription
IMMUNOSUPPRESSIVE AGENTS
Active ingredient group (AIG) number: 0157630001; AHFS:
APPROVED
2019-10-08
_ _ _ _ _ _ _ December 19, 2022_ _ _ _NUCALA, Mepolizumab _ _ Page 1 of 85_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION Pr NUCALA Mepolizumab for Injection 100 mg/mL lyophilized powder for subcutaneous injection Mepolizumab Injection 100 mg/mL solution for subcutaneous injection 40 mg/0.4 mL solution for subcutaneous injection Interleukin-5 (IL-5) inhibitor GlaxoSmithKline Inc. 100 Milverton Drive Suite 800 Mississauga, Ontario L5R 4H1 Date of Initial Authorization: DEC 03, 2015 Date of Revision: NOV 28, 2023 Submission Control No: 270798 _©_ _2022 GSK group of companies of its licensor _ _Trademarks are owned by or licensed to the GSK group of companies _ _ _ _ _ _ _ _ December 19, 2022_ _ _ _NUCALA, Mepolizumab _ _ Page 2 of 85_ RECENT MAJOR LABEL CHANGES SECTION DATE 1 INDICATIONS 11/2021 4 DOSAGE AND ADMINISTRATION, 4.1 Dosing Considerations 09/2022 4 DOSAGE AND ADMINISTRATION, 4.2 Recommended Dose & Dosage Adjustment 09/2022 4 DOSAGE AND ADMINISTRATION, 4.4 Administration 09/2022 4 DOSAGE AND ADMINISTRATION, 4.5 Missed Dose 09/2022 7 WARNINGS AND PRECAUTIONS, 7.1 Special Populations 11/2021 7 WARNINGS AND PRECAUTIONS, 7.1.1 Pregnant Women 11/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ......................................................................................... 2 TABLE OF CONTENTS ............................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ................................................................................ 4 1 INDICATIONS ...................................................................................................................... 4 1.1 Pediatrics .................................................................................................................................. 4 1.2 Geriatrics ............................................................................... Read the complete document